cyrilzakka/clinical-trials huggingface dataset:
The Accumbo Home Blood Pressure Trial

Aim of the study was to investigate a new clinical medical system for treatment of hypertension with a clinical decision system,a smartphone patient app and a home blood pressure monitor.

Despite the extensive knowledge of the importance of treating and thus preventing complications of hypertension, the incidence of high blood pressure is increasing, and it is still the main cause of cardiovascular disease and premature death, partly due to deficiencies in preventive care and control of the disease in an aging world. Blood pressure values obtained by self-measurement at home (HBPM) have been shown to predict the cardiovascular prognosis equally well as or better than blood pressure values obtained in the clinic (CBPM) in several observational studies. Aim of the present study was to investigate a new clinical medical system for treatment of hypertension with a clinical decision system and a electronic health record, a patient app and a home blood pressure monitor. " The patient app and the doctor's record reflect each other and basically contain the same information. Doctors can treat their patients remotely and the patients are able to manage some health issues by themselves by using the applications. Some patients need the physical examination. We therefore included patients after a so-called triage step with medical questions.

Eligibility Criteria:
Inclusion Criteria:

* Primary hypertension
* Smartphone at home

Exclusion Criteria:

* Secondary hypertension,
* previous stroke,
* myocardial infarction,
* known heart failure,
* known cardiac arrhytmia,
* known servere renal failure,
* known dementia
Intraoperative Confocal Laser Scanning Microscopy with Use of AI for Optimized Surgical Excision of Basal Cell Carcinoma

The aim is to use AI to assist surgeons in analyzing CLSM tissue slide images obtained during BCC surgeries with the aim to integrate it in real time. We plan to use AI to analyze CLSM images of BCCs and distinguish between tumor tissue, inflammatory tissue, and non-tumor/non-inflammatory tissue. This approach would provide surgeons with real-time feedback and automated image analysis, leading to a more targeted and efficient approach to tissue analysis. By improving the accuracy and speed of tissue analysis, our proposal could ultimately improve operative patient outcomes and benefit healthcare professionals.


Eligibility Criteria:
Inclusion Criteria:

* Patients with Basal Cell Carcinoma

Exclusion Criteria:

* Patient unable to consent
PET MYOCARDIAL Blood Flow Comparison to Coronary CTA and CT-FFR

The broad, long-term objective of this pilot study is to develop an optimal, clinically usable, non-invasive evaluation of Coronary Artery Disease (CAD) in the setting of stable angina which provides both anatomic and functional information.

Patients already scheduled to undergo Invasive coronary catheterization (ICA) for the clinical indication of angina will be recruited to under go stress-rest Positron Emission Tomography-Coronary CT Angiography-Fractional Flow Reserve (PET-cCTA-cFFR)

This is a single cohort, technology assessment study. Thirty-five patients presenting with stable angina and a moderate pretest likelihood for CAD who are already scheduled to undergo invasive coronary angiography (ICA) for the clinical indication of angina will be recruited to undergo a cCTA examination with FFR followed immediately by regadenoson stress-rest PET on the same PET/CT scanner.

Sensitivity, specificity, NPV, PPV of CTA-cFFR will be obtained using the reference standard of standard of care ICA with FFR for each epicardial coronary artery.

Segmental stress PET MBF will be compared to presence or absence of a coronary artery stenosis ≥ 50% diameter on CCTA and ICA.

Eligibility Criteria:
Inclusion Criteria:

* 18-90 years of age, of either sex
* Patients presenting with stable angina and a moderate pretest likelihood for CAD and scheduled to undergo ICA for the clinical indication of angina. Subjects will undergo this study within 45 days prior to the cardiac catheterization. This study can also be performed 45 days after the cardiac catheterization if the patient had no interventions.

Exclusion Criteria:

* Prior history of stenting, coronary artery bypass graft surgery, or myocardial infarction, unstable angina, atrial fibrillation, second or third degree atrioventricular block, class IV heart failure
* Iodine allergy
* Renal dysfunction (creatinine above normal laboratory limits)
* Symptomatic asthma
* Women who are pregnant or breast-feeding
Optimizing Cardiometabolic Health, Cognition and Academic Performance in Children (HAPHC)

Children and young people are moving less and less. In combination with an unhealthy diet, this has led to a sharp increase in overweight and obesity among children worldwide. Very often, physical illnesses occur in adolescence that can be directly attributed to the overweight and obesity. In order to protect children from these consequences in time, a daily exercise unit of 45 minutes is built into their learning. This exercise will take place in addition to physical education classes as part of your child's school day and will be conducted by a teacher. We will examine the children of the participating schools with regard to health-related characteristics.


Eligibility Criteria:
Inclusion Criteria:

* students in participating schools

Exclusion Criteria:

* none
Special Drug Use-results Surveillance of Tabrecta Tablets

This study is an uncontrolled, primary data collection-based observational study to be conducted as a central registration system, multicenter special drug-use results surveillance. As an all-case study, this study will collect all patients treated with Tabrecta in a specified post-marketing period. The observation period of each patient is up to 1 year (52 weeks)


Eligibility Criteria:
Inclusion Criteria:

* All patients receiving Tabrecta for MET exon 14 skipping mutation-positive unresectable advanced/recurrent NSCLC during a specified post-marketing period

Exclusion Criteria:

-
Therapeutic Education in Parkinson's Disease: What Impact on Drug Representations of Patients? (ETPARK-REMED)

Dopaminergic drug can have adverse effects leading to potential serious consequences. Therapeutic patient education must promote the understanding of drugs to improve its management. This study tries to evaluate the effect of therapeutic education workshop on Parkinson disease's drug (drug workshop) on the evolution of drug's representations in patients with Parkinson's disease compared to a control group.

Dopaminergic drug can have adverse effects leading to potential serious consequences. Therapeutic patient education must promote the understanding of drugs to improve its management.

The therapeutic educational program ETPARK includes individual's consults or workshop. The team frequently offer to patients to participate in workshop on Parkinson disease's drug.

This study tries to evaluate the effect of therapeutic education workshop on Parkinson disease's drug (drug workshop) on the evolution of drug's representations in patients with Parkinson's disease compared to a control group (speaking group) at 1 and 3 months.

Eligibility Criteria:
Inclusion Criteria:

* Patients with Parkinson's disease according to the United Kingdom Parkinson Disease Society Brain Bank (UKPDSBB) criteria,
* Patients who are already in therapeutic education program ETPARK,
* Patients who need and want to participate in therapeutic education workshop on Parkinson disease drug,
* Patients with health insurance,
* Patients who have signed a written informed consent form.

Exclusion Criteria:

* Patients suffering from another parkinsonian syndrome (multiple system atrophy, progressive supranuclear palsy etc.),
* Patients who has already done workshop on Parkinson disease drug (program ETPARK)
* Patients already included in clinical trial during the study,
* Patients who have severe psychiatric disorders or dopaminergic psychosis,
* Patients with cognitive impairment,
* Patients unable to complete the various scales used in the study,
* Patients under juridical protection,
* Women pregnant or breastfeeding.
Haemorrhoidectomy by Ligasure and Conventional Surgery

Comparison between Haemorrhoidectomy by Ligasure and conventional surgery

Hemorrhoids, a varicose condition are one of the commonest illnesses which causes per rectal bleeding . Hemorrhoidectomy is the standard operation for grades III and IV hemorrhoids; it is superior to any proposed conservative procedure. Conventional haemorrhoidectomy is the open surgical procedure in which the haemorrhoid pedicle is ligated by a transfixing suture which may lead to some postoperative complications mostly pain, bleeding and wound infection which ultimately cause prolonged stay in hospital.

A number of surgeons believe that by avoiding vascular pedicle ligation the chances of secondary bleeding can be decreased .This stimulated the researchers to develop new techniques with a less severe course and faster recovery . Recent advances in instrumental technology including the bipolar electrothermal device, ultrasonic scalpel, and circular stapler are gaining popularity as effective alternatives in hemorrhoidectomy . Of these instruments, the LigaSure vessel sealing system has been recently introduced as a tool conceived to upgrade the conventional treatment of haemorrhoids. This reduces anal spasm and allows performing a bloodless haemorrhoidectomy with reduced post- operative pain and fast healing . .Thus this operation can be recommended as the ideal technique. Many trials were performed to compare LigaSure hemorrhoidectomy with conventional hemorrhoidectomy, although an overall favorable trend exists toward LigaSure, conclusions are not univocal and definitive; this creates some uncertainty, also considering the increasing cost for this disposable device: thus it is essential to keep on experimenting to determine whenever an actual advantage exists.

Eligibility Criteria:
Inclusion Criteria:

* all patients with ages between 18 to 70 years with symptomatic grade III, or IV hemorrhoid who will be operated on at the Department of general Surgery, Assuit University Hospital

Exclusion Criteria:

* age older than 70 years
* patients with Grade I and II haemorrhoids
* patients on anticoagulants
* patients with liver cirrhosis
* patients with the hematological disorder
* patients with the concomitant anal disease
* patients had previous history of anorectal surgery
DNA Mutation Detection in Circulating Tumor DNA and Tissue by mmADPS for Pancreatic Cancer

Based on the cell free nucleic acid analysis information of blood samples and genetic mutation profile of EUS-FNB tissue from pancreatic cancer, the concordance between them is evaluated. And based on this information, biomarkers for diagnosis, treatment, and prognosis of pancreatic cancer are explored.


Eligibility Criteria:
Inclusion Criteria:

* Patients diagnosed with pancreatic cancer through histological or radiologic examination and before treatment begins
* Patients aged 18 or older who voluntarily agrees to participate in the study and is willing to understand and comply with the subsequent treatment procedures and sample collection schedule
* Among patients diagnosed with benign pancreatic diseases (pancreatic cyst, chronic pancreatitis, etc.), patients who have need for histological examination as control group

Exclusion Criteria:

* Where the subject himself/herself refuses to fill out the consent form or is unable to fill out the consent form
* If a laboratory test is impossible due to a qualitative problem with the collected blood sample
* Where the collected tissue does not contain tissue of the desired malignant or benign disease
Additional Effects of Mental Imagery Along With Task Oriented Training on Kinesiophobia in Patients With Stroke

The objective of this study to determine the effect of mental imagery and task oriented training on Kinesiophobia in stroke patients. And to determine the association of Kinesiophobia with gait and balance in stroke patients. Patients will be divided into experimental and control group. Randomized participants will be allocated into control and experimental group. The experimental group will receive 20 minutes of MI training followed by 25 minutes of TOT for a total of 45 minutes, 5 days per week for 6 weeks.

Cerebrovascular accident (CVA),commonly known as stroke , occurs when blood flow to the brain is disrupted , either by a clot or by rupture in a blood vessel .It can lead to severe neurological damaged or even death. A stroke can cause neurological deficits in various domains of brain areas, include motor, sensory/perceptive, visual, language, intelligence and emotion. Motor deficits are one of the most common and disabling consequences of stroke.

Kinesiophobia is a psychological condition characterized by an excessive, irrational fear of movement and physical activity due to the belief that it will increase pain or worsen a pre medical condition. It can be a common obstacle to rehabilitation and recovery for individuals with various musculoskeletal or neurological conditions, including stroke.

MI has been recognized as an effective adjunct therapy to physical rehabilitation for various neurological conditions, including stroke. Task-oriented training is a widely adopted approach in stroke rehabilitation, which emphasizes the practice of functional tasks to promote motor skill learning and improve motor function.

However the potential benefits of combining mental imagery with task-oriented train-ing have not been fully explored. Therefore studying the additional effects of mental imagery along with task-oriented training on Kinesiophobia in patients with stroke is important for developing more effective and comprehensive rehabilitation interven-tions for stroke populations.

Eligibility Criteria:
Inclusion Criteria:

* Hemiplegic stroke patients
* Age above 45
* Both genders
* Patients having score \>17 on Tempa Scale of Kinesiophobia
* Patients of score \>21 on Berg Balance Scale

Exclusion Criteria:

* • Communication deficits and unable to follow instructions

  * A history of serious or unstable cardiac condition
  * Severe musculoskeletal problem and unable to stand or walk
  * History of other neurological diseases or unilateral neglect
Magnet Resonance Imaging to Evaluate of Dynamic T2 Preparation Puls by Patients With Shunt or Chronic Obstructive Pulmonary Disease

There is preliminary evidence that a dynamic T2 Preparations Puls sequence by cardiac magnet resonance imaging can differentiate between oxygenated and deoxygenated blood.

In adult patients with inborn heart defects this has not yet been researched. Therefore,patients with ventriculoperitoneal shunt, septal and atrio-septal shunt should be examined. Also, patients with chronic obstructive pulmonary disease should be examined.

The aim of this study is the validation of a novel magnet resonance sequence in terms of a distinction of oxygenated blood to deoxygenated blood in comparison to invasive method of measuring cardiac catheterization.


Eligibility Criteria:
Inclusion Criteria:

* patients with atrial septal defect (ASD) or ventricular septal defect (VSD) and COPD
* written informed consent

Exclusion Criteria:

* patients with ST-elevation
* contraindication for MRI
* heavy kidney disease
* pregnant or breast feeding women
Clinical Evaluation Gastrointestinal Motility With PillCam

The purpose of this study is to evaluate the clinical usefulness of a video camera pill (PillCam) in assessing intestinal function in the small intestines of patients. It is believed that the condition of the subjects digestive system can have a large impact on their overall physical health. Therefore, the investigators would like to assess whether using the pill device helps to determine any functional problems in patients in the ICU. The investigators are studying ICU patients because any change in their condition can have a large impact on their recovery. The same device will be used in healthy subjects scheduled for elective ambulatory surgery.


Eligibility Criteria:
Inclusion Criteria:

* mild-to-moderate brain injury patients who suffered from traumatic or non-traumatic intracranial hemorrhage
* admitted to an intensive care unit (ICU)
* needed an enteral tube placed for feeding
* control (ambulatory) group consisted of outpatients with no history of major abdominal surgery

Exclusion Criteria:

* younger than 18 years
* suffered multiple injuries (especially abdominal trauma or inflammatory bowel disease)
* had a history of complicated or unknown abdominal surgery
* presented with clinical evidence of ileus or suspected obstruction
* Patients with a pacemaker
A Study to Compare the Bioavailability Intranasal Administration of 200 and 400 µg or 400 µg Alone of OPTINOSE™ FLUTICASONE With 440 µg of Flovent® HFA (Fluticasone Propionate) Inhalation Aerosol (Part 2)

To compare the systemic exposure of a single dose of 400 µg of OPTINOSE FLUTICASONE with 440 µg of Flovent® HFA (fluticasone propionate) Inhalation Aerosol in asthmatic subjects.


Eligibility Criteria:
Inclusion Criteria:

1. Male or female subjects' ages 18 to 55 years, inclusive, at screening.
2. Have a body mass index of 18 to 32 kg/m2, inclusive, and a body weight of not less than 52 kg for males and 45 kg for females.
3. Otherwise healthy mild to moderate asthmatic (Part 2) with no clinically relevant abnormalities in the opinion of the Investigator as determined by medical history, physical examination, blood chemistry, hematology (including complete blood count), serology, urinalysis, vital signs, and ECG performed at screening.
4. History of mild to moderate asthma, diagnosed by a physician, which is well controlled at the present time (no history of sudden or severe asthma exacerbation in the past 12 months).
5. Are unlikely to exacerbate during the study due to seasonal allergen exposure.
6. Able to tolerate withdrawal of their medication for a required period of time.

Exclusion Criteria:

1. Currently have or have a history of disease or dysfunction of the cardiovascular, endocrine, hematologic, neurological, immune, gastrointestinal, genitourinary, musculoskeletal, or other body system that is clinically significant in the opinion of the Investigator.
2. History of smoking or use of nicotine-containing substances within the previous 3 months before screening.
3. Hypersensitivity to fluticasone propionate or any of the excipients found in OPTINOSETM FLUTICASONE or Flovent® HFA (for Part 2).
4. History of extensive nasal and/or sinus surgery.
5. Known nasal obstruction including allergic rhinitis, nasal septal deviations, polyposis, severe mucosal swelling, nasal ulcers, nasal trauma or any other reason.
6. History of acute severe asthma attacks.
7. History of seasonal asthma exacerbation, in which case subjects should be outside the relevant allergen season.
8. Have evidence of any chronic medical conditions other than asthma requiring prescription medications (e.g., hypertension or diabetes).
9. Have used inhaled, intranasal, oral, or injectable corticosteroids within 4 weeks prior to dosing. Subjects should be on stable treatment for at least 1 month prior to withdrawal.
Effects Of Concentric Cycling Training Protocol During (Neo)Adjuvant Chemotherapy in Breast Cancer Patients: PROTECT-07 Study

The association of anthracyclines (ANT) and paclitaxel (Tax) is one of the main treatments used in breast cancer. These treatments are known to induce severe side effects such as a decrease in overall exercise capacity (physical condition) in response to muscle and cardiorespiratory alterations. If exercise may be an effective preventive strategy, it seems important to prescribe the most efficient exercise modality. Among them, concentric cycling (i.e., classic cycling) can significantly induce metabolic stimulus, which is needed for maintaining exercise capacity. The PROTECT-07 study aims to demonstrate the superiority of a training program based on concentric cycling during chemotherapy compared to standard treatment. The duration of the training program is 15 weeks with one session per week.

There will be two groups of patients after drawing lots using a process called randomization. The probability is one in two of being in the group participating in the training program, the other group following the standard treatment.

Eligibility Criteria:
Inclusion Criteria:

* Woman ≥ 18 years old
* Stage I to III breast cancer
* Patient currently planning (neo)adjuvant treatment combining anthracycline-cyclophosphamide and weekly paclitaxel (± trastuzumab)
* Affiliation to a social security system
* Able to speak, read and understand French

Exclusion Criteria:

* No prior chemotherapy treatment
* Any known cardiac or vascular pathology
* Contraindications to physical fitness assessment
* Protected adult
* Psychiatric, musculoskeletal or neurological problems
* Pregnant or breastfeeding woman (NB: this population is already subject to a contraindication to (neo)adjuvant treatment. For women of childbearing age, a betaHCG dosage is already carried out systematically before the start of chemotherapy and information on the need for contraception throughout the chemotherapy period is provided before the start of treatment. As part of this study, only the presence of this test with a negative result at the start of chemotherapy will be checked. inclusion, if available).
Study of the Effectiveness of "Fesia Grasp": Functional Electrical Stimulation Device for Upper Limb Rehabilitation After Stroke

The purpose of this study is to evaluate the effectiveness of Fesia Grasp, a Functional Electrical Stimulation device for the rehabilitation of upper limb in post-stroke patients. Fesia Grasp rehabilitation will be compared with usual care rehabilitation of upper limb.

* Experimental group: patients will receive Fesia Grasp therapy (intensive, repetitive and functional exercises assisted by functional electrical stimulation)
* Control group - patients will receive standard care.


Eligibility Criteria:
Inclusion Criteria:

* 18 years old or older subjects with hemiparesis in the upper limb after stroke, which have been referred to the Rehabilitation Unit of the Reina University Hospital.
* Unilateral paresis
* Cognitive ability to assimilate and actively participate in the protocol of evaluation and treatment

Exclusion Criteria:

* Very severe proximal spasticity: Ashworth \> 3.
* Psychiatric illness (including post-stroke depression).
* Cognitive impairment.
* Inability to provide informed consent.
* Other severe medical problems.
* Severe hemi-spatial neglect or anosognosia involving the affected arm.
* Pacemakers
* Pregnant women.
* Skin ulcers.
* Peripheral neuropathies.
* Edema of the affected forearm and / or hand.
* Severe pain.